耐药性是癌症治疗和抗癌药物开发的主要障碍。越来越多的证据表明，非编码 RNA (ncRNA)，特别是 microRNA (miRNA)、长链非编码 RNA (lncRNA) 和环状 RNA (circRNA)，在癌症进展、治疗和耐药性中发挥着关键作用。此外，ncRNA 已被证明是有前途的癌症治疗新靶点。通过药物逆转失调的 ncRNA 作为克服耐药性的有效治疗策略具有巨大的潜力。因此，我们开发了 ncRNADrug，这是一个集成的综合资源，记录手动策划和计算预测的与耐药性相关的 ncRNA、药物靶向的 ncRNA 以及用于治疗耐药癌症的潜在药物组合。目前，ncRNADrug 收集了 29 551 个经过实验验证的条目，涉及与 266 种药物耐药性相关的 9195 个 ncRNA（2248 个 miRNA、4145 个 lncRNA 和 2802 个 circRNA），以及 32 969 个条目，涉及 10 480 个 ncRNA（4338 个 miRNA、6087 个 lncRNA 和 55 个 circRNA）。 965 种药物。此外，ncRNADrug 还包含通过差异表达分析从 ncRNA 表达谱预测的 ncRNA 和药物之间的关联。总的来说，ncRNADrug无论在数据量还是功能上都超越了现有的相关数据库。它将成为药物开发和癌症治疗的有用资源。 ncRNADrug 可在 http://www.jianlab.cn/ncRNADrug 获取。© 作者 2023。由牛津大学出版社代表 Nucleic Acids Research 出版。

Drug resistance is a major barrier in cancer treatment and anticancer drug development. Growing evidence indicates that non-coding RNAs (ncRNAs), especially microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), play pivotal roles in cancer progression, therapy, and drug resistance. Furthermore, ncRNAs have been proven to be promising novel therapeutic targets for cancer treatment. Reversing dysregulated ncRNAs by drugs holds significant potential as an effective therapeutic strategy for overcoming drug resistance. Therefore, we developed ncRNADrug, an integrated and comprehensive resource that records manually curated and computationally predicted ncRNAs associated with drug resistance, ncRNAs targeted by drugs, as well as potential drug combinations for the treatment of resistant cancer. Currently, ncRNADrug collects 29 551 experimentally validated entries involving 9195 ncRNAs (2248 miRNAs, 4145 lncRNAs and 2802 circRNAs) associated with the drug resistance of 266 drugs, and 32 969 entries involving 10 480 ncRNAs (4338 miRNAs, 6087 lncRNAs and 55 circRNAs) targeted by 965 drugs. In addition, ncRNADrug also contains associations between ncRNAs and drugs predicted from ncRNA expression profiles by differential expression analysis. Altogether, ncRNADrug surpasses the existing related databases in both data volume and functionality. It will be a useful resource for drug development and cancer treatment. ncRNADrug is available at http://www.jianglab.cn/ncRNADrug.© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.